All News

gout target T2T

Treat-to-Target in Gout and Cardiovascular Outcomes

Jack Cush, MD

A 5 year JAMA study shows that a treat-to-target (serum urate < 6 mg/dL) study finds that effective urate-lowering treatment (ULT) results in a significantly reduced cardiovascular risk in patients with gout. 

Read Article
death

Trends in Rheumatoid Arthritis Mortality

Jack Cush, MD

A recent study examines trends in rheumatoid arthritis (RA)-related mortality among U.S. postmenopausal women (aged 55 and older). They found RA mortality rates have declined, yet disparities in who is most affected persist, especially for white women, and those over 85 yrs of age.

Read Article
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
lung,cancer,blue,mass

BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs

Jack Cush, MD

A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. 

Read Article
early.RA_.jpg

APPIPRA Study - Benefits of Early Treatment

EurekAlert!

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

Read Article
APR MTX Cover

Methotrexate

Jack Cush, MD

In this session, Dr. Jack Cush reviews methotrexate.

Read Article
joint.pain_.hand_.PIP_.jpg

Are JAK Inhibitors Better at Pain Relief in RA?

MedPage Today

Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.

Read Article
restless.legs.feet.spasm

Review of Restless Legs Syndrome

Jack Cush, MD

JAMA has published a full read review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia.

Read Article
emergency.jpg

Emergency Department Visits by Rheumatoid Patients

Jack Cush, MD

A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population controls.

Read Article
Joint.pain.hands.blue

Smartphones and Rheumatoid Flares

Jack Cush, MD

FORWARD Databank of Rheumatoid arthritis (RA) patients reveals that smartphone data can predict flares using PROs. 

Read Article
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

Dr. John Cush RheumNow ( View Tweet)

Advanced Practice Rheum: Methotrexate https://t.co/PHAFWBG4gJ https://t.co/p9cMqT4nhR

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

Dr. John Cush RheumNow ( View Tweet)

APPIPRA Study - Benefits of Early Treatment Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped. https://t.co/hgxj936CWn https://t.co/eJX3amp3Id

Links:

Dr. John Cush RheumNow ( View Tweet)
UCAN CAN-DU study of 181 JIA pts starting biologics. Early Rx w/in 6 mos (n=35) assoc. w/ greater odds of achieving inactive arthritis (83% vs 57% in late starters (>12 mos). For each month of delay increased the odds of future active arthritis (after 6 mos) by 9%.

Dr. John Cush RheumNow ( View Tweet)

Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf
Dr. John Cush RheumNow ( View Tweet)
Preoperative Semaglutide for 3 mos. prior to Total Knee Arthroplasty assoc w/ signif less Postoperative Adverse Events in NIDDM. Retrospective study of up to 745 T2DM needed TKR . 2-3 mos of GLP-1a reduces serious AEs by 75% (OR 0.25, P < 0.001). https://t.co/re57y9OvTN https://t.co/KNirmfdr2F

Links:

Dr. John Cush RheumNow ( View Tweet)
German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV

Links:

Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/ruZM3Qftxb
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of recombinant zoster vaccine Rheumatic (RMD) pts on DMARDs (32% JAKi) (114) vs 65 normals. HZoster reactivation: no controls vs 1in RMD. 1 Dz flare requiried steroids. Minor AE (ISR, HA, myalgia) seen in 17.5% & 21.5% w/ 1st & 2nd dose. RZV is safe in RMD https://t.co/Mu3OyA4EOD
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×